Author Contributions: Dr Andersen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Andersen, Kragstrup, Søndergaard.
Acquisition of data: Andersen.
Analysis and interpretation of data: Andersen, Søndergaard.
Drafting of the manuscript: Andersen, Søndergaard.
Critical revision of the manuscript for important intellectual content: Andersen, Kragstrup, Søndergaard.
Statistical analysis: Andersen.
Obtained funding: Andersen, Kragstrup, Søndergaard.
Administrative, technical, or material support: Kragstrup.
Study supervision: Kragstrup, Søndergaard.
Financial Disclosures: Dr Andersen reported receiving fees from the Danish Association of the Pharmaceutical Industry for teaching at pharmacoepidemiology courses in 2001, 2002, 2004, and 2005. Dr Søndergaard has reported receiving a fee on 1 occasion after submission of this article for giving a lecture at an AstraZeneca symposium. Dr Kragstrup reported no disclosures.
Funding/Support: The original SymbiAC clinical trial was sponsored by AstraZeneca, Denmark. AstraZeneca funded the observational cohort study of effects on prescribing patterns presented in this article and another ongoing study, in which the authors participate. Funding was provided as a grant to the Research Unit for General Practice in Odense.
Role of the Sponsor: The sponsor contributed with data on the SymbiAC trial. The sponsor did not get insight into prescription data at the level of the individual physicians or patients and was not involved in the design of the study, the management, analysis, and interpretation of the data, the preparation, review, or approval of the manuscript, or the decision to submit it for publication.
Acknowledgment: We thank Henrik Støvring, MSc, PhD, for statistical advice (Research Unit for General Practice, University of Southern Denmark). Dr Støvring did not receive payment related to this project and has no relationship with AstraZeneca.